Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

• Үндсэн зохиолчид: Magdalena Zajac (Зохиогч), Marietta Scott (Зохиогч), Marianne Ratcliffe (Зохиогч), Paul Scorer (Зохиогч), Craig Barker (Зохиогч), Hytham Al-Masri (Зохиогч), Marlon C. Rebelatto (Зохиогч), Jill Walker (Зохиогч)
• Формат: Ном
• Хэвлэсэн: BMC, 2019-09-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Background Antibodies targeting the programmed cell death-1 (PD-1)/PD-ligand 1 (PD-1/PD-L1) checkpoint have shown promising clinical activity in patients with advanced urothelial carcinoma (UC). Expression of PD-L1 in UC tumors has been investigated using different antibody clones, staining...